Dronabinol

Generic Name
Dronabinol
Brand Names
Marinol, Sativex, Syndros
Drug Type
Small Molecule
Chemical Formula
C21H30O2
CAS Number
1972-08-3
Unique Ingredient Identifier
7J8897W37S
Background

Dronabinol (marketed as Marinol) is a synthetic form of delta-9-tetrahydrocannabinol (Δ⁹-THC), the primary psychoactive component of cannabis (marijuana). THC demonstrates its effects through weak partial agonist activity at Cannabinoid-1 (CB1R) and Cannabinoid-2 (CB2R) receptors, which results in the well-known effects of smoking cannabis such as increased ...

Indication

Dronabinol is indicated for the treatment of anorexia associated with weight loss in patients with AIDS, and nausea and vomiting associated with cancer chemotherapy in patients who have failed to respond adequately to conventional antiemetic treatments.

Associated Conditions
Anorexia, Chemotherapy-Induced Nausea and Vomiting
Associated Therapies
-
Clinical Trials
Related News

A Study to Assess the Pharmacokinetic (PK) Properties of Sativex® in Patients With Advanced Cancer

Phase 1
Withdrawn
Conditions
Advanced Cancer
Interventions
Drug: Sativex
First Posted Date
2015-05-04
Last Posted Date
2016-03-02
Lead Sponsor
GW Pharmaceuticals Ltd
Registration Number
NCT02432612

Cannabinoids, Learning, and Memory

Phase 1
Active, not recruiting
Conditions
Cannabis
Psychotic Disorders
Interventions
Drug: THC
Drug: Placebo
First Posted Date
2015-04-03
Last Posted Date
2023-10-13
Lead Sponsor
Yale University
Target Recruit Count
80
Registration Number
NCT02407808
Locations
🇺🇸

VA Connecticut Healthcare System, West Haven, Connecticut, United States

N-acetylcysteine Effects on Tetrahydrocannabinol

Early Phase 1
Terminated
Conditions
Healthy
Interventions
Drug: Delta-9-THC
Drug: Placebo
Drug: N-acetylcysteine
First Posted Date
2015-01-09
Last Posted Date
2022-01-31
Lead Sponsor
Yale University
Target Recruit Count
5
Registration Number
NCT02335060
Locations
🇺🇸

VA Connecticut Healthcare System, West Haven, Connecticut, United States

A Study to Evaluate the Pharmacokinetics Of Sativex® in Subjects With Severe Renal Impairment or End Stage Renal Disease, Compared to Matched Subjects With Normal Renal Function.

Phase 1
Withdrawn
Conditions
Renal Insufficiency
Kidney Disease
Interventions
Drug: Sativex
First Posted Date
2014-12-24
Last Posted Date
2016-08-11
Lead Sponsor
GW Pharmaceuticals Ltd
Registration Number
NCT02325024

Influence of a Medicinal Cannabinoid Agonist on Responses to Food Images and Food Intake

Not Applicable
Active, not recruiting
Conditions
Appetite Regulation
Interventions
Drug: Placebo
Drug: dronabinol
First Posted Date
2014-12-08
Last Posted Date
2024-07-10
Lead Sponsor
Universitaire Ziekenhuizen KU Leuven
Target Recruit Count
18
Registration Number
NCT02310347
Locations
🇧🇪

University Hospitals Leuven, campus Gasthuisberg, Leuven, Belgium

Effects of THC and CBD on Human Episodic Memory Function

First Posted Date
2014-11-14
Last Posted Date
2015-01-16
Lead Sponsor
Central Institute of Mental Health, Mannheim
Target Recruit Count
20
Registration Number
NCT02291562
Locations
🇩🇪

Central Institute of Mental Health, Mannheim, Germany

Processing of Salient Emotional Stimuli as a Function of Tetrahydrocannabinol (THC) and Cannabidiol (CBD)

First Posted Date
2014-11-14
Last Posted Date
2015-01-16
Lead Sponsor
Central Institute of Mental Health, Mannheim
Target Recruit Count
20
Registration Number
NCT02291536
Locations
🇩🇪

Central Institute of Mental Health, Mannheim, Germany

Anesthetic Premedication With a Cannabis Extract (Cannapremed)

First Posted Date
2014-11-05
Last Posted Date
2024-02-28
Lead Sponsor
Hadassah Medical Organization
Target Recruit Count
200
Registration Number
NCT02283281
Locations
🇮🇱

Hasassah - Hebrew University Ein Kerem Medical Center, Jerusalem, Israel

A Randomised, Open-label, Three-way Crossover Study to Assess the Pharmacokinetics and Safety of Single Doses of Four Sprays of Sativex® in a Range of Oral pH Environments in Healthy Subjects

Phase 1
Terminated
Conditions
Healthy Volunteers
Interventions
Drug: Sativex
First Posted Date
2014-09-15
Last Posted Date
2021-02-05
Lead Sponsor
GW Pharmaceuticals Ltd
Target Recruit Count
6
Registration Number
NCT02240160

The Role of the Endocannabinoid System in Sweet Taste Intensity and Liking

First Posted Date
2014-04-11
Last Posted Date
2017-05-23
Lead Sponsor
Wageningen University
Target Recruit Count
10
Registration Number
NCT02112292
Locations
🇳🇱

Wageningen University, Wageningen, Gelderland, Netherlands

© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy